N-丁基-6-氯-5-硝基-4-嘧啶胺 | 492464-18-3

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: N-丁基-6-氯-5-硝基-4-嘧啶胺
• 英文名称: butyl-(6-chloro-5-nitro-pyrimidin-4-yl)-amine
• 英文别名: 6-Chlor-5-nitro-4-butylamino-pyrimidin；N-butyl-6-chloro-5-nitropyrimidin-4-amine
• CAS: 492464-18-3
• 化学式: C₈H₁₁ClN₄O₂
• 分子量: 230.654
• InChiKey: SLMDKWYHHCRFSE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  83.6
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  N-丁基-6-氯-5-硝基-4-嘧啶胺 在 sodium tetrahydroborate 、 氨 、 N,N-二异丙基乙胺 、 nickel dichloride 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 25.5h， 生成 9-butyl-8-(3,4,5-trimethoxy-benzyl)-9H-purin-6-ylamine
  参考文献：
  名称：

  Adenine derived inhibitors of the molecular chaperone HSP90—SAR explained through multiple X-ray structures

  摘要：

  Multiple co-crystal structures of an adenine-based series of inhibitors bound to the molecular chaperone Hsp90 have been determined. These structures explain the observed SAR for previously described compounds and new compounds, which possess up to 8-fold improved potency against the isolated enzyme. Anti-tumour cell potency and mechanism of action data is also described for the most potent compounds. These data should enable the design of more potent Hsp90 inhibitors. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.11.011
• 作为产物：
  描述：

  4,6-二氯-5-硝基嘧啶 、 正丁胺 在 碳酸氢钠 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 N-丁基-6-氯-5-硝基-4-嘧啶胺
  参考文献：
  名称：

  通过5-氨基-4-氯-6-烷基氨基嘧啶与N，N-二甲基链烷酰胺和醇盐离子的反应有效地一锅合成6-烷氧基-8,9-二烷基嘌呤

  摘要：

  许多新的6-烷氧基-8,9-（二取代）嘌呤的合成是通过将相应的中间体5-氨基-4-氯-6-（烷基氨基）嘧啶经醇盐和各种N促进的环化来完成的，N-二甲基酰胺，后者用作溶剂-试剂。通过这种三组分缩合反应，我们能够在嘌呤环的8位引入烷基，同时用烷氧基部分亲核取代6-氯。

  DOI：

  10.1016/s0040-4020(02)00867-0

文献信息

• An efficient one-pot synthesis of 6-alkoxy-8,9-dialkylpurines via reaction of 5-amino-4-chloro-6-alkylaminopyrimidines with N,N-dimethylalkaneamides and alkoxide ions
  作者：Pier Giovanni Baraldi、Asier Unciti Broceta、Maria Josè Pineda de las Infantas、Juan Josè Dı̀az Mochun、Antonio Espinosa、Romeo Romagnoli

  DOI：10.1016/s0040-4020(02)00867-0

  日期：2002.9

  ines has been accomplished by the cyclization of the corresponding intermediate 5-amino-4-chloro-6-(alkylamino)pyrimidines promoted by alkoxides and various N,N-dimethyl amides, where the latter act as solvent–reagents. By this three-component condensation reaction we are able to introduce an alkyl group in the 8 position of the purine ring with the concomitant nucleophilic replacement of the 6-chloro

  许多新的6-烷氧基-8,9-（二取代）嘌呤的合成是通过将相应的中间体5-氨基-4-氯-6-（烷基氨基）嘧啶经醇盐和各种N促进的环化来完成的，N-二甲基酰胺，后者用作溶剂-试剂。通过这种三组分缩合反应，我们能够在嘌呤环的8位引入烷基，同时用烷氧基部分亲核取代6-氯。
• New synthetic route to diaminonitropyrazoles as precursors of energetic materials
  作者：Jérôme Guillard、Fanny Goujon、Perrine Badol、Didier Poullain

  DOI：10.1016/s0040-4039(03)01301-7

  日期：2003.7

  Treatment of nitropyrimidine derivatives with (N-substituted) hydrazines (2 equiv.) gave 1-(substituted)-3,5-diamino-4-nitropyrazole, providing a very mild conversion of pyrimidines into pyrazoles. This reaction provided a convenient route to precursors for new efficient and insensitive explosives.

  用（N-取代的）肼（2当量）处理硝基嘧啶衍生物得到1-（取代的）-3,5-二氨基-4-硝基吡唑，提供嘧啶非常温和的转化为吡唑。该反应为制备新型高效和不敏感炸药的前体提供了便利的途径。
• Adenine derived inhibitors of the molecular chaperone HSP90—SAR explained through multiple X-ray structures
  作者：Brian Dymock、Xavier Barril、Mandy Beswick、Adam Collier、Nicholas Davies、Martin Drysdale、Alexandra Fink、Christophe Fromont、Roderick E. Hubbard、Andrew Massey、Allan Surgenor、Lisa Wright

  DOI：10.1016/j.bmcl.2003.11.011

  日期：2004.1

  Multiple co-crystal structures of an adenine-based series of inhibitors bound to the molecular chaperone Hsp90 have been determined. These structures explain the observed SAR for previously described compounds and new compounds, which possess up to 8-fold improved potency against the isolated enzyme. Anti-tumour cell potency and mechanism of action data is also described for the most potent compounds. These data should enable the design of more potent Hsp90 inhibitors. (C) 2003 Elsevier Ltd. All rights reserved.